Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David Hale | CEO, MD & GM | 998.04k | -- | 1968 |
| Mr. Philippe Bourrinet | Chief Pharmacist, Deputy CEO, Senior VP of Development, Medical & Regulatory Affairs and Deputy MD | 11.5k | -- | 1968 |
| Mr. Jerome Estampes | CFO and Senior VP of Business Development & Licensing | -- | -- | -- |
| Ms. Sarah Dayre | Senior VP of Technical Operations & Interim Chief Pharmacist | -- | -- | -- |
| Ms. Charlotte Bamiere | Director of Legal Affairs | -- | -- | -- |
| Christine Allard | Senior Vice President of Public Affairs & Corporate Communications | -- | -- | -- |
| Eva Ohlsson | Senior Vice President of Human Resources | -- | -- | -- |
| Mr. Jean-Francois Blanc | Senior Vice President of Interventional Imaging | -- | -- | -- |
| Mr. Francois Nicolas | Senior VP of R&D, R&I and Chief Digital Officer | -- | -- | 1971 |
| Ms. Valérie Brissart | Senior Vice President of Diagnostic Imaging | -- | -- | -- |
Guerbet SA
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 2,920
Description
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.
Corporate Governance
Upcoming Events
March 25, 2025 at 3:00 PM UTC
Guerbet SA Earnings Date
Recent Events
July 1, 2024 at 12:00 AM UTC
Ex-Dividend Date